Form 4: RAPT Therapeutics CSO Granted 100,000 Stock Options

Dirk G. Brockstedt, Chief Scientific Officer of RAPT Therapeutics, Inc., was granted 100,000 employee stock options with a vesting schedule over four years.

Summary

• Dirk G. Brockstedt, the Chief Scientific Officer of RAPT Therapeutics, Inc. (RAPT), was granted 100,000 employee stock options.
• The options have an exercise price of $7.43 per share.
• The grant date and vesting commencement date for these options is June 20, 2025.
• The options will vest over a period of 48 months, with 1/48th of the shares vesting on each monthly anniversary of the vesting commencement date.
• The expiration date for these stock options is June 19, 2035.

Sentiment

Score: 6

Explanation: Slightly positive. While a routine compensation event, it signifies continued executive incentive and retention, which is generally positive for company stability and long-term strategy, though it also implies potential future dilution.

Positives

• The grant of 100,000 stock options provides a significant incentive for the Chief Scientific Officer, aligning his interests with long-term shareholder value.
• The vesting schedule over four years encourages long-term commitment and retention of a key executive.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• The value of the stock options is dependent on the future performance of RAPT Therapeutics' stock price; if the stock price does not exceed the exercise price of $7.43, the options may not be in-the-money.
• Future market conditions and company performance could impact the ultimate value realized from these options.

Future Outlook

The stock options are subject to a four-year vesting schedule, with monthly vesting commencing on June 20, 2025, indicating a long-term incentive structure for the Chief Scientific Officer.

Industry Context

This is a standard executive compensation practice within the biotechnology and pharmaceutical industries, where equity grants are commonly used to attract, retain, and incentivize key scientific and leadership talent.

Comparison to Industry Standards

• The grant of 100,000 stock options to a Chief Scientific Officer is a common form of equity compensation in the biotech sector, comparable to practices at similar-sized biopharmaceutical companies.
• A four-year vesting schedule with monthly increments is a typical industry standard designed to ensure long-term executive retention and alignment with shareholder interests, similar to vesting schedules observed at companies like Moderna or BioNTech for their key executives.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized executive performance.
• Employees: Reinforces the company's compensation structure and commitment to retaining key talent.

Next Steps

• Continued monthly vesting of the 100,000 stock options over the next 48 months, starting June 20, 2025.

Key Dates

Keywords

RAPT Therapeutics, RAPT, Stock Options, Employee Stock Option, SEC Form 4, Insider Transaction, Chief Scientific Officer, Executive Compensation, Equity Grant, Vesting Schedule